Publications by authors named "Shinpei Yoshida"

Claim this Profile
S
Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate.
Ryo Ohashi, Shuichi Otake, Tatsuhiko Murata, Ryosuke Watari, Shinpei Yoshida

Pharmaceutics· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Involvement of P-gp and BCRP in Oral Absorption of Ensitrelvir, An Oral SARS-CoV-2 3C-like Protease Inhibitor, in a Non-Clinical Investigation.
Ryosuke Watari, Naomi Tamura, Shinpei Yoshida, Yasuto Kido, Takanobu Matsuzaki

J Pharm Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Haruaki Nobori, Keiko Baba, Takayuki Kuroda, Kaoru Baba, Kazumi Matsumoto, Shinpei Yoshida

Antiviral Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses.
Takayuki Kuroda, Keita Fukao, Shinpei Yoshida, Ryoko Oka, Kaoru Baba

Viruses· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Takayuki Kuroda, Haruaki Nobori, Keita Fukao, Kaoru Baba, Kazumi Matsumoto, Shinpei Yoshida

J Antimicrob Chemother· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
Michihito Sasaki, Koshiro Tabata, Mai Kishimoto, Yukari Itakura, Hiroko Kobayashi, Shinpei Yoshida

Sci Transl Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of Human-Induced Pluripotent Stem Cell-Derived Functional Enterocyte-Like Cells for Pharmacokinetic Studies.
Shinpei Yoshida, Takayuki Honjo, Keita Iino, Ryunosuke Ishibe, Sylvia Leo

Stem Cell Reports· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of intestinal organoids derived from human pluripotent stem cells for drug testing.
Shinpei Yoshida, Hiroto Miwa, Tomoyuki Kawachi, Shoen Kume, Koji Takahashi

Sci Rep· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The elucidation of key factors for oral absorption enhancement of nanocrystal formulations: In vitro-in vivo correlation of nanocrystals.
Masaaki Imono, Hiromasa Uchiyama, Shinpei Yoshida, Shiro Miyazaki, Naomi Tamura

Eur J Pharm Biopharm· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine.
Takanori Akazawa, Shinpei Yoshida, Shuichi Ohnishi, Takushi Kanazu, Makoto Kawai

Drug Metab Dispos· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The first total synthesis of nidulalin A, a dihydroxanthone possessing multiple bioactivities.
Kuniaki Tatsuta, Shusuke Yoshihara, Nobutaka Hattori, Shinpei Yoshida, Seijiro Hosokawa

J Antibiot (Tokyo)· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis